{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-078752","form_type":"8-K","ticker":"SGMT","cik":"0001400118","company_name":"Sagimet Biosciences Inc.","filed_at":"2025-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.892596+00:00","generated_at":"2026-05-17T12:59:17.811815+00:00","sec_items":["1.01","1.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Sagimet Biosciences enters $75M ATM equity facility with Leerink Partners, terminates prior Cantor facility","bullets":["Up to $75M in common stock may be sold from time to time via at-the-market offerings through Leerink Partners.","Agent commission of up to 3.0% on gross proceeds from sales under the agreement.","Prior Cantor Fitzgerald ATM agreement terminated effective Aug 14, 2025; no shares were sold under that facility."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-078752","json":"https://secwatch.observer/filing/0001104659-25-078752.json","markdown":"https://secwatch.observer/filing/0001104659-25-078752.md","text":"https://secwatch.observer/filing/0001104659-25-078752.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1400118/000110465925078752/0001104659-25-078752-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1400118/000110465925078752/tm2523529d2_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T12:59:17.811815+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}